0001104659-23-020900.txt : 20230214 0001104659-23-020900.hdr.sgml : 20230214 20230214091448 ACCESSION NUMBER: 0001104659-23-020900 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230213 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duran Felipe CENTRAL INDEX KEY: 0001964267 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 23623290 MAIL ADDRESS: STREET 1: 8800 HSC PARKWAY CITY: BRYAN STATE: TX ZIP: 77807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 3 1 tm236684-1_3.xml FORM 3 X0206 3 2023-02-13 0 0001420720 iBio, Inc. IBIO 0001964267 Duran Felipe C/O IBIO, INC., 8800 HSC PARKWAY BRYAN TX 77807 0 1 0 0 Interim CFO Common Stock (RSU) 2133 D Stock Option (Right to Buy) 32.25 2022-05-04 2031-05-04 Common Stock 2800 D Stock Option (Right to Buy) 31.50 2022-08-23 2031-08-23 Common Stock 1000 D Stock Option (Right to Buy) 7.00 2022-08-29 2031-08-29 Common Stock 12000 D Consists of 2,133 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 2,133 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. These RSUs will vest in even increments on the first three anniversaries of grant, subject to the conditions of the Plan and grant agreement. 25% of options granted will vest one year following the grant date; and after one year following the grant date, 6.25% of the options granted will vest for each additional 3 months of employment, subject to the conditions of the Plan and grant agreement. /s/ Felipe Duran 2023-02-14